The 2nd International mRNA Health Conference

Posted by: RNA-Seq Blog in Conferences November 10, 2014 7,786 Views

The time is right to give therapeutic mRNA a special forum.

mRNA – the molecule whose medical use seemed almost out of reach until a few years ago – is now in substantial progress to become a new class of drugs. mRNA may transform the treatment of many human diseases and disorders.

The 2nd International mRNA Health Conference, which will be held on November 11 and 12, 2014, in Cambridge, Massachusetts, will bring together more than 150 attendees from leading international pharmaceutical and biotechnology companies and academic institutions. During the two-day event, colleagues from around the world will share the vanguard of research and technologies poised to unlock the tremendous medical potential of mRNA for many therapeutic indications.

Conference Program

Tuesday, November 11th

8:00 am	Opening registration and reception
9:00 am	Welcome remarks by the Organizing Committee

Introductory Sessions

9:30 am	Jack Szostak, Massachusetts General Hospital, 2009 Nobel Prize in Physiology or Medicine mRNA and the origin of life
10:00 am	John Reynders, Moderna Therapeutics Is mRNA like software?
10:30 am	Phil Sharp, MIT Institute, 1993 Nobel Prize in Physiology or Medicine Non-coding RNA in the synthesis and regulation of mRNA

11:00 am	Coffee Break

11:30 am	Ingmar Hoerr, CureVac Optimizing mRNA for versatile medical approaches
12:00 pm	Ugur Sahin, BioNTech mRNA for Individualized Cancer Immunotherapy

12:30 pm	Lunch Break

1:30 pm	Session Vaccines
1:30 pm	Chair introduction by Ugur Sahin, BioNTech
1:35 pm	Andrew Geall, Novartis
2:05 pm	Steve Pascolo, University Hospital of Zurich
2:35 pm	Ulrike Gnad-Vogt, CureVac
3:05 pm	Kris Thielemans, University of Brussels

3:35 pm	Coffee Break

3:55 pm	Session Therapeutics
3:55 pm	Chair introduction by Rahul Kakkar, AstraZeneca
4:00 pm	Regina Fritsche-Danielson, AstraZeneca
4:30 pm	Ken Chien, Karolinska University
5:00 pm	Carsten Rudolph, Ethris
5:30 pm	Igor Splawski, Novartis Institutes for BioMedical Research

6:00 pm	Session End

Networking Evening State Room Boston

6:15 pm	Bus to Reception Dinner
7:00 pm	Reception Dinner with Scientific Poster Session

Wednesday, November 12, 2014

8:00 am	Breakfast

9:00 am	Panel Discussion Vaccines
	Chaired by: Ugur Sahin, BioNTech Panelists: Andrew Geall, Novartis Steve Pascolo, University Hospital of Zurich Ulrike Gnad-Vogt, CureVac Kris Thielemans, University of Brussels

10:00 am	Coffee Break

10:30 am	Panel Discussion Therapeutics
	Chaired by: Stephane Bancel, Moderna Therapeutics Panelists: Regina Fritsche-Danielson, AstraZeneca Ken Chien, Karolinska University Carsten Rudolph, Ethris Igor Splawski, Novartis Institutes for BioMedical Research

11:30 am	Panel Discussion mRNA Products & Manufacturing
	Chaired by: Ingmar Hoerr, CureVac Panelists: Steve Harbin, Moderna Therapeutics Peter Hutt, Former FDA General Counsel Andreas Kuhn, BioNTech Anton McCaffrey, TriLink Florian von der Mülbe, CureVac

12:30 pm	Lunch Break

1:30 pm	Peter Hutt, Former FDA General Counsel FDA Regulation of mRNA Biological Drugs
2:00 pm	Dan Wattendorf, DARPA Impact of mRNA on Global Health
2:30 pm	Closing remarks by the Organizing Committee

3:00 pm	End of conference